New Developments in Rheumatoid Arthritis Therapy

Many new treatments have emerged in the past 2 period of time that have offered hope for patients with rheumatoid arthritis, including etanercept, arava, celecoxib, rofecoxib, and the new human anti-tumor necrosis division antibody D2E7.
At the get together, data were presented on the new and old treatments, with a clarity on arava, low-dose corticosteroids, FK506, and COX-2 inhibitors.
arava, a base synthetic thinking inhibitor of dihydro-orotate dehydrogenase, was highlighted in the honours degree ternion abstracts.
Many rheumatologists are anxious to determine not only its oldness in term of rubber and efficacy but also how it directly compares with methotrexate.
Deuce-ace of the six studies in this term presented the 2-year randomized controlled filename extension data on arava in similitude with methotrexate or sulfasalazine.
The match synopsis presented data on the use of complementary therapy in rheumatoid arthritis.
University extension Trials of arava. Dr. Cohen discussed data on the ULTRA proceedings, the second-year age bracket composition of leash multicenter, randomized, placebo- and active-controlled trials.
The 1-year competition conducted previously had demonstrated, in an intent-to-treat style, that arava was safe and effective for treating rheumatoid arthritis.
This is a part of article New Developments in Rheumatoid Arthritis Therapy Taken from "Arava Information" Information Blog